Company / Accounts Receivable
ENDONOVO THERAPEUTICS, INC. Accounts Receivable History
FY2011-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$944
FY2021
5-year range
$942 / $22.7K
FY2017-FY2021
Trend
+0.2%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $22,742 to $944 over the past 2 years.
Based on SEC 10-K filings.
$944 in FY2021 with a 10-year CAGR of -3.7%.
Declined from $22,742 to $944 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -34.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -3.7%
Key checks
Key Insights
- 3-year CAGR of -34.4%, indicating a declining trend.
- In FY2021, accounts receivable increased 0.2% year-over-year.
- Peak accounts receivable was recorded in FY2019.
- Lowest accounts receivable in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | $944 | +0.2% |
| FY2020 | $942 | -95.9% |
| FY2019 | $22.7K | +579.9% |
| FY2018 | $3.3K | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | - | - |
| FY2011 | $1.4K | - |
As of FY2021 · SEC 10-K · Updated Jun 29, 2026